Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

70.76 +0.01 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 385,836
Open 70.83
Bid (Size) 70.24 (1)
Ask (Size) 73.24 (3)
Prev. Close 70.75
Today's Range 69.99 - 72.57
52wk Range 52.50 - 72.57
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Keep Off Your Radar
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory

Performance

YTD
+27.6%
+27.6%
1 Month
+5.7%
+5.7%
3 Month
+19.7%
+19.7%
6 Month
+19.9%
+19.9%
1 Year
+8.0%
+8.0%

More News

Read More
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
A Peek at ANI Pharmaceuticals's Future Earnings
Via Benzinga
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Stocks Supply Chain
Exposures Supply Chain US Equities
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
3 Russell 2000 Stocks in the Doghouse
Via StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
1 Growth Stock to Target This Week and 2 to Avoid
Via StockStory
Exposures COVID-19
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today
Via StockStory
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
Via Benzinga
Get insights into the top gainers and losers of Friday's pre-market session.
Via Chartmill
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars
Via StockStory
Earnings Scheduled For February 28, 2025
Via Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is ANI Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ANI Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ANI Pharmaceuticals, Inc. - Common Stock trade on?
ANI Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ANI Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ANI Pharmaceuticals, Inc. - Common Stock is ANIP on the Nasdaq Stock Market
What is the current price of ANI Pharmaceuticals, Inc. - Common Stock?
The current price of ANI Pharmaceuticals, Inc. - Common Stock is 70.76
When was ANI Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ANI Pharmaceuticals, Inc. - Common Stock was at 04/29/25 04:00 PM ET
What is the market capitalization of ANI Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ANI Pharmaceuticals, Inc. - Common Stock is 1.73B
How many shares of ANI Pharmaceuticals, Inc. - Common Stock are outstanding?
ANI Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.